Announcement
13 Nov 2020
On 13 November 2020, BARDA provided $454.3 million funding to Janssen Pharmaceuticals to support their COVID-19 vaccine Phase 3 clinical trials in adults.
Source
Sign in to access
Number of interventions
1
1 certainly harmful
0 likely harmful
0 liberalising
List of interventions
Implementation date
13 Nov 2020
Revocation date:
No revocation date
Updated: 13 Nov 2020
State aid, unspecified
In force
On 13 November 2020, the U.S. Department of Health and Human Services (HHS), Biomedical Advanced Research and Development Authority (BARDA) announced providing USD 454.3 million funding to Janssen ...
Sign in to see more
Related State Acts
25 Mar 2021
United States of America: BARDA provides funding to Janssen Pharmaceuticals to support their COVID-19 vaccine Phase 2a clinical trials trial to include adolescents
21 Aug 2020
United States of America: BARDA provides $85.3 million funding to Janssen Pharmaceuticals to support Janssen’s COVID-19 vaccine phase 2 clinical trials and additional non-clinical studies
05 Aug 2020
United States of America: BARDA and DOD collaborates with Janssen Pharmaceuticals for the production of investigational COVID-19 vaccine doses
27 Mar 2020
United States of America: BARDA provides $435 million funding to Janssen Pharmaceuticals to support Janssen’s vaccine candidate through phase 3 clinical trials
11 Feb 2020
United States of America: BARDA collaborates with Janssen Pharmaceuticals to accelerate clinical trials and manufacturing of COVID-19 vaccine
Threads
See all
This state act is not part of any Thread yet.